Ferric bepectate is a patented total-dosage iron therapy with a unique formulation and a promising pharmacokinetic profile. Unlike some currently available IV iron formulations, our product is based on modified starch rather than dextran. Once approved and launched, ferric bepectate is expected to fill a significant gap in the market for IV iron treatments capable of providing the high dose therapy without compromising patient safety.
We have encapsulated iron nanoparticles in such a way that they form a larger and stronger complex than other IV iron products. This means ferric bepectate can deliver high doses of intravenous iron in one setting, while ensuring that it is rapidly cleared from the plasma, thus minimizing the patient’s exposure to free iron.
The API is developed and produced by Serumwerk Bernburg.
The final pharmaceutical product will be produced in a cooperation with several contract manufactures.